AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$AMGN

Amgen (NASDAQ:AMGN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations

Amgen (AMGN) reported Q3 2026 revenue of $10.37B, up 8.5% YoY and 3.1% above estimates. Adjusted EPS of $6.45 beat estimates by 11.6%. Full-year revenue guidance raised to $39.3B, up 1.3%. Operating margin was 45.1%, stable YoY. Shares fell 2.2% post-results.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amgen (NASDAQ:AMGN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AMGNBearishHigh
01

Why it matters

The earnings beat and guidance lift provide fresh data for traders, but the immediate share decline suggests market caution.

02

Market read

First report of Amgen's Q3 results and guidance, material for biotech investors.

03

What to watch

Amgen's strong operating margin and pipeline progress may sustain longer‑term upside despite the near‑term dip.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Amgen's Q3 2026 earnings were released, showing revenue growth and an uplift in full‑year guidance.

Company-level read

Ticker impact

$AMGNBearishHigh confidence
Context

Amgen reported Q3 2026 results beating revenue and EPS estimates and raised full-year guidance.

Expected impact

likely pressure as the market prices in modest guidance lift and profit beat

Evidence & confidence

The earnings beat was offset by a modest guidance increase and a post‑earnings price decline.

Market effects

Sector

Biotech sector may see slight pullback as Amgen's modest guidance tempers growth expectations.

Regional

U.S. large‑cap biotech index could see marginal downside.

Global

Limited; impact confined to U.S. biotech and related ETFs.

Counterpoint

What could challenge this read

The beat and guidance raise could support a short‑term bounce if investors focus on the positive numbers.

Key entities

  • Executive
    Robert A. Bradway

    CEO of Amgen, quoted on the results.

Read at source← All news

StoryAmgen posts Q3 2026 earnings beat and lifts full‑year revenue and EPS guidance

Also covered by

5 outlets

Related articles

NOV 4
$AMGNMedAI 8/10

What Amgen (AMGN) Said on Its Q3 Earnings Call

Amgen reported Q3 sales growth in rare diseases and oncology, with BLINCYTO up 27% and TEPEZZA down 6%. Positive phase III results were announced for small cell lung cancer, eosinophilic esophagitis, and Sjögren's disease. MariTide obesity drug trials are advancing. Amgen raised 2026 revenue guidance to $38.9B-$39.7B and EPS to $22.90-$23.70, with a 6% dividend increase.

finance.yahoo.com7 min
NOV 3
$AMGNHighAI 9/10

AMGN Q3 FY2026 earnings call

Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, with 17 products growing double-digit. Non-GAAP operating margin was 47%, and free cash flow reached $3.7B. The company raised full-year 2026 guidance, expecting revenue of $38.9B-$39.7B and EPS of $22.90-$23.70. Key growth drivers include Repatha, EVENITY, TEZSPIRE, and UPLIZNA, with notable increases in rare disease and oncology portfolios.

finance.biggo.com2 min